Press Releases

Creative Proteomics Cytokine Launches Growth Factors (GF) Detection Service for Your Research

Creative Proteomics Launches SPR-based Biacore Service to Help Study Biomolecular Interactions

CRISPR Off-Target Analysis Now Available with CD Genomics’ Bioinformatics-Analysis Platform

CD Genomics RNA-Solutions Platform Unveils m7G MeRIP Sequencing for Scientific Research

Alfa Chemistry Commenced Offering PTFE (Polytetrafluoroethylene), Optical Fibers, and Diamond Raw Materials

Creative Enzymes Offers Personalized and Customized Probiotic Blends

Creative Enzymes Introduces Cloning Enzymes for Molecular Biology Research

Oxygen-, Nitrogen-, Carbon-Donor Ligands for Coordination Chemistry Research

Protection Reagents, Environmental Goods Standards, Porphyrins and Phthalocyanines

API Supply Enriched by Adding Lenalidomide, Parecoxib Sodium, and Rivaroxaban

Wendy Buckland to Join Emmes as Chief Operating Officer

100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)

Aptevo's APVO436 was found to show a clinical benefit in a Phase 1 study as part of a combination therapy with venetoclax and azacitidine

Global Clinical Trials Connect 2023

“Collaboration, Innovation and Enhancing Quality in Clinical Trials”Conference, Expo and Workshop

Global Pharmaceutical Company Merz Choose Generis’ CARA Life Sciences Platform to Consolidate their R&D Content

Generis has announced that Merz has selected Generis' CARA™ Life Sciences Platform for managing all the documents in their R&D process.

HighTide Therapeutics and Quotient Sciences Announce Agreement to Conduct a 14C Human ADME Program for HTD1801

Integrated Synthesis-to-Clinic® Program Will Support HTD1801’s Clinical Development and Regulatory Submission Package

Lifeasible Released an Exclusive Qualitative and Quantitative Pollen Composition Analysis Service

Creative Biostructure Supports Bacteriophage Research with iEM Platform

ONWARD Reports Interim Clinical Outcomes for Implantable ARC Therapy Demonstrating Potential to Improve Blood Pressure Regulation after Spinal Cord Injury

ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury (SCI), today reported interim clinical outcomes from the first ten[1] people treated to regulate blood pressure with implantable ARC Therapy, ONWARD’s targeted spinal cord stimulation technique. ARC Therapy immediately improved blood pressure levels for all participants; this benefit has been sustained for the duration of the current follow-up period. Participants have also reported improved quality of life, increased energy and vitality, and reduced dizziness.

OVER £175 MILLION FOR CUTTING-EDGE GENOMICS RESEARCH TO HELP BOOST DIAGNOSIS AND TREATMENT FOR PATIENTS

Genomics England has announced funding of £105 million to kickstart a world-leading research study, in partnership with the NHS, to explore the effectiveness of using whole genome sequencing to find and treat rare genetic diseases in newborn babies.

Three Featured Products Upgraded at Alfa Chemistry: Protection Reagents, Environmental Goods Standards, Porphyrins and Phthalocyanines

On the occasion of Thanksgiving and Christmas, Alfa Chemistry would like to express its sincere gratitude to its global customers. In addition to discounts and exquisite gifts offered to ordering customers, the company also continuously improves its product lines. Fairly recently, Alfa Chemistry announced the upgrade of its featured products, i.e., protection reagents, environmental goods standards, as well as porphyrins and phthalocyanines, supporting better user experience and wider choices for customers across the world.